Abstract 5725: Targeting Rac1 as a therapeutic vulnerability in T-cell lymphomas
Lucero Alvarado(Pontificia Universidad Católica Argentina), Florencia Cayrol(Consejo Nacional de Investigaciones Científicas y Técnicas), Goergina A. Cardama(National University of Quilmes), G Gonzalez(Instituto de Investigaciones Biomédicas en Retrovirus y Sida), Mercedes Debernardi(Instituto de Investigaciones Biomédicas en Retrovirus y Sida), Helena Sterle(Pontificia Universidad Católica Argentina), Barrozo Julio(Hospital Británico de Buenos Aires), Jorgelia Real(Hospital Británico de Buenos Aires), Silvina Palmer(Hospital Británico de Buenos Aires), Valeria G. Sanchez(Instituto de Investigaciones Biomédicas en Retrovirus y Sida), S Rivarola(Hospital Británico de Buenos Aires)
Cited by 0
Related Papers
THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors
|Nature Communications|2017|108
Immunomodulatory role of histamine H4 receptor in breast cancer
|British Journal of Cancer|2018|35
Thyroid status modulates T lymphoma growth via cell cycle regulatory proteins and angiogenesis
|Journal of Endocrinology|2014|22
Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma
|Molecular Cancer Therapeutics|2022|6
SUN-LB054 Cilengitide Reverts Thyroid Hormones Effects in Bexarotene Treatment of Breast Cancer Cells
|Journal of the Endocrine Society|2019|1